vantictumab (OMP-18R5) - Mereo Biopharma, Bayer
Morphosys: J.P. Morgan Healthcare Conference (Morphosys) - Jan 19, 2014 - Anticipated data from P1 trial for solid tumors in 2014; Anticipated data from P1 trial for pancreatic cancer in 2015; Anticipated data from P1 trial for NSCLC in 2015; Anticipated data from P1 trial for breast cancer in 2015 
Anticipated P1 data Breast Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer
http://www.morphosys.com/sites/default/files/phone_conferences/140113-16_MOR-Company%20Update_JPM_presentation_final.pdf
 
Jan 19, 2014
 
.
 
586271f7-328b-4951-8a8a-d546277760fd.jpg